JP Morgan Initiates Coverage On Rhythm Pharmaceuticals with Overweight Rating, Announces Price Target of $145

Benzinga Newsdesk www.benzinga.com Neutral 78.6%

Neg 0% Neu 78.6% Pos 0%

JP Morgan analyst Priyanka Grover initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight rating and announces Price Target of $145.